34 assets in Graft Versus Host Disease

Therapeutic assets addressing Graft Versus Host Disease, rated under Floatz methodology v0.2 and sorted by current rating.

Asset	Sponsor	Phase	Rating
Busulfanum Graft Versus Host Disease	City of Hope Medical Center	P4	BBB (74)
Cyclophosphamide Graft Versus Host Disease	City of Hope Medical Center	P4	BBB (74)
Thiotepa Graft Versus Host Disease	Memorial Sloan Kettering Cancer Center	P4	BBB (73)
Nivestim Graft Versus Host Disease	City of Hope Medical Center	P4	BBB (72)
Cyclosporin A Graft Versus Host Disease	Memorial Sloan Kettering Cancer Center	P3	BB (71)
Ruxolitinib Graft Versus Host Disease	Jonathan Brammer	P4	BB (70)
Anti-Human T-Lymphocyte Immunoglobulin, Rabbit Graft Versus Host Disease	Assistance Publique - Hôpitaux de Paris	P4	BB (68)
Fludarabine Graft Versus Host Disease	City of Hope Medical Center	P3	BB (68)
Melphalan Graft Versus Host Disease	City of Hope Medical Center	P2	BB (68)
Methotrexate Graft Versus Host Disease	University of Michigan Rogel Cancer Center	P3	BB (68)
Tacrolimus Graft Versus Host Disease	City of Hope Medical Center	P3	BB (68)
Etoposide Graft Versus Host Disease	Memorial Sloan Kettering Cancer Center	P2	BB (67)
Alemtuzumab Graft Versus Host Disease	Monica Bhatia	P2	BB (66)
Sirolimus Graft Versus Host Disease	Zachariah Michael DeFilipp	P3	BB (66)
Ibrutinib Graft Versus Host Disease	Pharmacyclics Switzerland GmbH	P4	BB (64)
Oxygen Graft Versus Host Disease	Jay C. Buckey Jr.	P4	BB (64)
Anti-Human T-Lymphocyte Immunoglobulin From Rabbits Graft Versus Host Disease	Assistance Publique - Hôpitaux de Paris	P3	B (60)
Equine Atg Graft Versus Host Disease	DKMS gemeinnützige GmbH	P3	B (60)
Panobinostat Graft Versus Host Disease	Novartis Pharmaceuticals	P4	B (60)
Clofarabine Graft Versus Host Disease	Memorial Sloan Kettering Cancer Center	P2	B (59)
Pentostatin Graft Versus Host Disease	National Heart, Lung, and Blood Institute (NHLBI)	P2	B (59)
Abatacept Recombinant Graft Versus Host Disease	Emory University	P2	B (58)
Apamistamab Graft Versus Host Disease	Actinium Pharmaceuticals	P2/3	B (57)
Blinatumomab Graft Versus Host Disease	Bambino Gesù Hospital and Research Institute	P2/3	B (57)
Vorinostat Graft Versus Host Disease	University of Michigan Rogel Cancer Center	P2	B (57)
Hpc, Cord Blood Graft Versus Host Disease	Memorial Sloan Kettering Cancer Center	P2	CCC (53)
Vedolizumab Graft Versus Host Disease	City of Hope Medical Center	P2	CCC (50)
Mesna Graft Versus Host Disease	Dana-Farber Cancer Institute	P1	CC (43)
Treg-Enriched Donor Cell Graft Versus Host Disease	Dana-Farber Cancer Institute	P1	CC (43)
trx103 Graft Versus Host Disease	Tr1X, Inc.	P1	CC (43)
Emapalumab Graft Versus Host Disease	City of Hope Medical Center	P1	CC (41)
Sodium Butyrate Graft Versus Host Disease	City of Hope Medical Center	P1	CC (41)
Sodium Propionate Anhydrous Graft Versus Host Disease	City of Hope Medical Center	P1	CC (41)
Donor T Cells Graft Versus Host Disease	Dana-Farber Cancer Institute	P1	D (30)